These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

423 related items for PubMed ID: 10764688

  • 1. Comparative in vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet-mediated clot strength induced by tissue factor with use of thromboelastography: differentiation among glycoprotein IIb/IIIa antagonists.
    Mousa SA, Khurana S, Forsythe MS.
    Arterioscler Thromb Vasc Biol; 2000 Apr; 20(4):1162-7. PubMed ID: 10764688
    [Abstract] [Full Text] [Related]

  • 2. Comparison of the effect of different platelet GPIIb/IIa antagonists on the dynamics of platelet/fibrin-mediated clot strength induced using thromboelastography.
    Mousa SA, Forsythe MS.
    Thromb Res; 2001 Oct 01; 104(1):49-56. PubMed ID: 11583738
    [Abstract] [Full Text] [Related]

  • 3. Monitoring platelet glycoprotein IIb/IIIa-fibrin interaction with tissue factor-activated thromboelastography.
    Khurana S, Mattson JC, Westley S, O'Neill WW, Timmis GC, Safian RD.
    J Lab Clin Med; 1997 Oct 01; 130(4):401-11. PubMed ID: 9358079
    [Abstract] [Full Text] [Related]

  • 4. Differential efficacy of different platelet glycoprotein IIb/IIIa antagonists on platelet/fibrin-mediated clot dynamics under different conditions using thrombelastography: the critical need for anticoagulant.
    Mousa SA, Forsythe MS, Bozarth JM.
    Coron Artery Dis; 2002 Jun 01; 13(4):243-8. PubMed ID: 12193852
    [Abstract] [Full Text] [Related]

  • 5. Regulation of clot retraction by glycoprotein IIb/IIIa antagonists.
    Seiffert D, Pedicord DL, Kieras CJ, He B, Stern AM, Billheimer JT.
    Thromb Res; 2002 Nov 01; 108(2-3):181-9. PubMed ID: 12590956
    [Abstract] [Full Text] [Related]

  • 6. Comparative efficacy of different low-molecular-weight heparins (LMWHs) and drug interactions with LMWH: implications for management of vascular disorders.
    Mousa SA.
    Semin Thromb Hemost; 2000 Nov 01; 26 Suppl 1():39-46. PubMed ID: 11011805
    [Abstract] [Full Text] [Related]

  • 7. In-vitro efficacy of different platelet glycoprotein IIb/IIIa antagonists and thrombolytics on platelet/fibrin-mediated clot dynamics in human whole blood using thrombelastography.
    Mousa SA.
    Blood Coagul Fibrinolysis; 2007 Jan 01; 18(1):55-60. PubMed ID: 17179828
    [Abstract] [Full Text] [Related]

  • 8. Using thrombelastography to determine the efficacy of the platelet glycoprotein IIb/IIIa antagonist, roxifiban, on platelet/fibrin-mediated clot dynamics in humans.
    Mousa SA, Bozarth JM, Seiffert D, Feuerstein GZ.
    Blood Coagul Fibrinolysis; 2005 Apr 01; 16(3):165-71. PubMed ID: 15795533
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of platelet-mediated clot retraction by integrin antagonists.
    Hantgan RR, Mousa SA.
    Thromb Res; 1998 Mar 15; 89(6):271-9. PubMed ID: 9669749
    [Abstract] [Full Text] [Related]

  • 10. Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels.
    Mousa SA, Bozarth JM, Forsythe MS, Slee A.
    Cardiovasc Res; 2000 Sep 15; 47(4):819-26. PubMed ID: 10974231
    [Abstract] [Full Text] [Related]

  • 11. Comparative antiplatelet efficacy of a novel, nonpeptide GPIIb/IIIa antagonist (XV454) and abciximab (c7E3) in flow models of thrombosis.
    Abulencia JP, Tien N, McCarty OJ, Plymire D, Mousa SA, Konstantopoulos K.
    Arterioscler Thromb Vasc Biol; 2001 Jan 15; 21(1):149-56. PubMed ID: 11145947
    [Abstract] [Full Text] [Related]

  • 12. Comparative analysis of various platelet glycoprotein IIb/IIIa antagonists on shear-induced platelet activation and adhesion.
    Wang X, Dorsam RT, Lauver A, Wang H, Barbera FA, Gibbs S, Varon D, Savion N, Friedman SM, Feuerstein GZ.
    J Pharmacol Exp Ther; 2002 Dec 15; 303(3):1114-20. PubMed ID: 12438534
    [Abstract] [Full Text] [Related]

  • 13. Comparative efficacy between the glycoprotein IIb/IIIa antagonists roxifiban and orbofiban in inhibiting platelet responses in flow models of thrombosis.
    Mousa SA, Abulencia JP, McCarty OJ, Turner NA, Konstantopoulos K.
    J Cardiovasc Pharmacol; 2002 Apr 15; 39(4):552-60. PubMed ID: 11904529
    [Abstract] [Full Text] [Related]

  • 14. Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity.
    Pedicord DL, Thomas BE, Mousa SA, Dicker IB.
    Thromb Res; 1998 Jun 15; 90(6):247-58. PubMed ID: 9700855
    [Abstract] [Full Text] [Related]

  • 15. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion.
    Rossi F, Rossi E, Pareti FI, Colli S, Tremoli E, Gallo L.
    Haematologica; 2001 Feb 15; 86(2):192-8. PubMed ID: 11224490
    [Abstract] [Full Text] [Related]

  • 16. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: importance of internal pool of glycoprotein IIb-IIIa receptors.
    Gawaz M, Ruf A, Pogatsa-Murray G, Dickfeld T, Rüdiger S, Taubitz W, Fischer J, Müller I, Meier D, Patscheke H, Schömig A.
    Thromb Haemost; 2000 Jun 15; 83(6):915-22. PubMed ID: 10896249
    [Abstract] [Full Text] [Related]

  • 17. Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban.
    Mousa SA, Bozarth JM, Naik UP, Slee A.
    Br J Pharmacol; 2001 Jun 15; 133(3):331-6. PubMed ID: 11375248
    [Abstract] [Full Text] [Related]

  • 18. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.
    Berny-Lang MA, Jakubowski JA, Sugidachi A, Barnard MR, Michelson AD, Frelinger AL.
    J Am Heart Assoc; 2013 May 15; 2(3):e000026. PubMed ID: 23676293
    [Abstract] [Full Text] [Related]

  • 19. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa.
    Schneider DJ, Taatjes DJ, Sobel BE.
    Cardiovasc Res; 2000 Jan 14; 45(2):437-46. PubMed ID: 10728364
    [Abstract] [Full Text] [Related]

  • 20. Effects of glycoprotein IIb/IIIa antagonists on platelet activation: development of a transfer method to mimic peak to trough receptor occupancy.
    Billheimer JT, He B, Spitz SM, Stern AM, Seiffert D.
    Thromb Res; 2002 Sep 15; 107(6):303-17. PubMed ID: 12565717
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.